WO2015024420A1 - 局麻药止痛延时剂 - Google Patents
局麻药止痛延时剂 Download PDFInfo
- Publication number
- WO2015024420A1 WO2015024420A1 PCT/CN2014/081969 CN2014081969W WO2015024420A1 WO 2015024420 A1 WO2015024420 A1 WO 2015024420A1 CN 2014081969 W CN2014081969 W CN 2014081969W WO 2015024420 A1 WO2015024420 A1 WO 2015024420A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anesthesia
- analgesic
- local
- local anesthetic
- delay agent
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract description 14
- 238000002690 local anesthesia Methods 0.000 title abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 29
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 25
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 25
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 8
- 239000011720 vitamin B Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims abstract description 5
- 230000000202 analgesic effect Effects 0.000 claims description 44
- 239000003589 local anesthetic agent Substances 0.000 claims description 41
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 30
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 15
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 4
- 229960003072 epinephrine hydrochloride Drugs 0.000 claims description 3
- 229940046001 vitamin b complex Drugs 0.000 claims 3
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 abstract description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 229960000907 methylthioninium chloride Drugs 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 description 28
- 230000037005 anaesthesia Effects 0.000 description 28
- 238000001356 surgical procedure Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 150000003505 terpenes Chemical class 0.000 description 20
- 235000007586 terpenes Nutrition 0.000 description 20
- 230000036592 analgesia Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000003444 anaesthetic effect Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 8
- 229960004194 lidocaine Drugs 0.000 description 8
- 238000002316 cosmetic surgery Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960005015 local anesthetics Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 5
- 229960003150 bupivacaine Drugs 0.000 description 5
- 238000002695 general anesthesia Methods 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000001640 nerve ending Anatomy 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000944 nerve tissue Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 229960002372 tetracaine Drugs 0.000 description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 206010022086 Injection site pain Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000703 anti-shock Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- 238000007443 liposuction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229960005094 prilocaine hydrochloride Drugs 0.000 description 2
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000012820 exploratory laparotomy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- -1 nocardaine Chemical compound 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to the field of surgical anesthesia for humans and animals, and more particularly to a local anesthetic analgesic delay agent. Background technique
- general anesthesia or local anesthesia there are only two types of anesthesia options for various operations: general anesthesia or local anesthesia, referred to as general anesthesia or local anesthesia.
- General anesthesia - refers to an anesthetic method that achieves analgesic purposes by temporarily suppressing the central nervous system of the brain and temporarily disabling the patient.
- general anesthesia requires a full-time anesthesiologist and proprietary anesthesia equipment. The risk of surgery is high, postoperative care is complicated, and patients cannot take care of themselves.
- CN1075081A contains chlorhexidine hydrochloride, tetracaine hydrochloride, hemostasis, carboxymethylcellulose, liquid sarcophagus and gentamicin sulfate.
- the formulation extended the anesthesia time from about 115 minutes to about 156 minutes, i.e., about 2.5 hours, by means of colloidalizing the anesthetic.
- each unit dosage form contains: dopamine 0.1 ⁇ lOOmg
- Multivitamin B 0.5 ⁇ 20mg
- the dosage form has an onset time of 3 to 5 minutes and anesthesia and analgesia for 3 to 9 days.
- VBi, VB 2 , VB 6 , VBi2, terpene blue, dexamethasone, etc. are sensitive to nerve tissue, can selectively act on nerve endings, block the transmission of pain nerves, and thus play a local analgesic effect.
- the present inventors have conducted extensive studies on the effects of multivitamins VBi, VB 2 , VB 6 , VB 12 , terpene blue, dexamethasone, sodium hydrogencarbonate and the like on prolonging analgesic time.
- VBi - chloramine hydrochloride participates in the normal function of muscle and nerve tissue.
- VB 2 - riboflavin involved in carbohydrate, fat, amino acid metabolism.
- VB 6 - pyridoxine hydrochloride involved in the formation of amino acids, fat metabolism and neurotransmitters.
- VBi2 - has the function of improving, nourishing, repairing nerve tissue cells, and maintaining the integrity of the myelin sheath of the nervous system. It can treat nervous system diseases such as neuritis, neuralgia, nerve atrophy and so on.
- Terpene blue - a redox agent for cyanide poisoning and methemoglobinemia. This product can also be used for urinary tract infections, urinary calculi, renal function tests, and local analgesic effects for neurodermatitis.
- Dexamethasone - has anti-inflammatory, anti-allergic, anti-viral, anti-shock properties. 5 % sodium bicarbonate - weak base. It can neutralize the stimulation of local acid products that reduce pain, promote the spread of anesthetics, and shorten the onset time.
- dexamethasone has anti-inflammatory, anti-allergic, anti-shock, anti-virus effects by consulting a large amount of data.
- Dexamethasone has anti-inflammatory, anti-allergic, anti-shock, anti-virus effects by consulting a large amount of data.
- there is also a reduction in the pain sensation of local tissue which may be related to the reduction of tissue compression and the elimination of edema.
- Terpene blue is a hydrogen-receiving body. It has a strong affinity for nerve endings after coloring. It can compete with other receptors, selectively acts on nerve endings, and reversely blocks pain nerve conduction and causes local pain.
- the surgical field can be blue-stained, the anatomical level is unclear, the operation time is prolonged, the operation risk is increased, and more seriously, it is proved by animal experiments that the high concentration (>0.03 %) can directly damage
- the nerve endings medulla resulting in irreversible damage to the nerves, so it is harmless to the human body only in the conventional range, and combined with the multivitamin B can complement each other, effectively reducing and repairing nerve damage.
- the inventors' body double upper limbs, abdomen, thighs
- comparative experiments were conducted on the inventors' relatives, friends, and volunteers, and more than 30 trials were conducted.
- the success rate is 100% and then officially used in the clinic. Since 1997, more than 13,000 cases of various operations have been completed, and no failures or side effects have occurred.
- each unit dosage form contains:
- Multivitamin B 0.5 - 20 mg
- the local anesthetic analgesic delaying agent according to the first aspect wherein the multivitamin B is composed of VB ⁇ VB 2 , VB 6 and VB 12 in any weight ratio.
- the local anesthetic analgesic delaying agent according to any one of claims 1 to 3, which further comprises 0.05 to 0.2 mg of adrenaline hydrochloride.
- the local anesthetic analgesic delaying agent of the present invention is a composition for use in combination with a surgical anesthetic.
- the composition itself does not contain any anesthetic component, but can enhance the analgesic effect of the local anesthetic used in combination therewith. Shorten the onset time and significantly prolong the anesthesia and analgesia time.
- doctors and anesthesiologists may select local anesthetics as appropriate, and these local anesthetics may be combined in a single combination or in combination.
- the "0.9% physiological saline" in the above technical solution 1 does not itself have an anesthetic or analgesic effect, but is used to adjust the concentration of the drug at the time of injection.
- the "balance” refers to the amount required to make up the volume of liquid required for the injection.
- the doctor can add 1% adrenaline hydrochloride according to the condition at the time of surgery to improve the safety of the operation.
- the amount of the local anesthetic analgesic delaying agent of the present invention may vary depending on the amount of the anesthetic and the size of the surgical site and the length of the operation.
- the multivitamin B of the above scheme can be composed of various vitamin Bs in any weight ratio. Generally, commercially available multivitamin B can be used, but preferably VBi, VB 2 , VB 6 , VB12 is composed of any weight ratio. More preferably, the multivitamin B is composed of VBi, VB 2 , VB 6 , and VB12 in a weight ratio (10 to 30 ) : ( 1 to 4 ) : ( 10 to 30 ) : ( 10 to 20 ).
- the range of amounts of each component given in the above technical solution refers to the amount of the anesthetic compound used in a single surgical anesthesia.
- the amount of local anesthetic analgesic delaying agent can be reduced with the reduction of the amount of anesthetic agent when performing minor surgery or when the time required for analgesia is short, and conversely, performing a larger operation.
- the amount of the local anesthetic analgesic delaying agent should be increased as the amount of the anesthetic agent is increased, but these variations are all within the scope of the present invention.
- the present invention has the following beneficial effects:
- the local anesthesia time can be as long as 30 ⁇ 40 days, or even longer, no additional analgesic is needed after surgery, which improves the safety of the operation. (The onset time of a single local anesthetic takes about 3 to 5 minutes, and the anesthesia time is about 60 to 120 minutes).
- Comparative Example 1 Facial cutting
- the distribution ratio of local anesthetic analgesic delay agent is:
- Multivitamin B 0.5mg
- the above ingredients were added to 4 ml of 0.375% of bupivacaine hydrochloride, 0.9% physiological saline was added to 8 ml, and then a 2.5 cm injection needle was used, subcutaneously injected into the inventors' 2 eyebrows, and each eyebrow portion was injected. According to a needle insertion point and a depth of 0.2 cm for subcutaneous injection, the above 8 ml local anesthetic was injected along the direction of the two eyebrows. The result was: 5 minutes onset, painfulness during injection, anesthesia and analgesic time from the original 5 to 10 hours lasts until 72 hours.
- the distribution ratio of local anesthetic analgesic delay agent is:
- the distribution ratio of local anesthetic analgesic delay agent is:
- the above ingredients were added to 15 ml of 0.375% of bupivacaine hydrochloride, 0.9% physiological saline was added to 30 ml, and then a 5 cm injection needle was used to perform layer-by-layer injection around the tumor along the skin and subcutaneous tissue.
- the results obtained were: 60 seconds onset, no pain during injection, and anesthesia and analgesia lasted from 72 hours to 40 days. (The required bupivacaine is reduced by one-fifth of the original, which improves the safety and quality).
- the distribution ratio of local anesthetic analgesic delay agent is:
- the above ingredients were added to 20 ml of 0.375 % of bupivacaine hydrochloride, 0.9% physiological saline was added to 40 ml, and then a 3 cm injection needle was used to stratify the skin and subcutaneous tissue along the incision line.
- the results obtained were: 60 seconds of onset, no pain during injection, and anesthesia and analgesia lasted from 72 hours to 40 days. (The required bupivacaine is reduced by a factor of five, which improves the safety and quality).
- the distribution ratio of local anesthetic analgesic delay agent is:
- Multivitamin B 0.5mg
- the distribution ratio of local anesthetic analgesic delay agent is:
- the above ingredients were added in proportion to a 1% solution of prilocaine hydrochloride in 30 ml, 0.9% water for injection was added to 60 ml, and then a subcutaneous, intramuscular, and subperiosteal injection was performed on the surgical site of the patient with a 3 cm injection needle.
- the onset time of anesthesia was shortened from 5 minutes for pure lidocaine to 60 seconds, and the duration of analgesia was extended from 2 hours to 40 days. It can be seen that after the use of the present invention, the onset time of the anesthetic can be significantly shortened, and the duration of sustained analgesia is extended by about 400 times. (The amount of demand for multi-cards is one-fifth less than the original, which improves the safety and quality)
- the distribution ratio of local anesthetic analgesic delay agent is:
- Multivitamin B 0.5mg
- the distribution ratio of local anesthetic analgesic delay agent is:
- the distribution ratio of local anesthetic analgesic delay agent is:
- the distribution ratio of local anesthetic analgesic delay agent is:
- the above ingredients were added in proportion to 2% lidocaine 80 ml solution, 1% hydrochloric acid epinephrine O.lmg was added, 0.9% physiological saline was added to 160 ml, and then subcutaneously performed on the patient's surgical site with a 3 cm injection needle. , muscle and subperiosteal injection, the results obtained is that the onset time of anesthesia is shortened from 5 minutes of pure lidocaine to 60 seconds, and the duration of analgesia is extended from 2 hours to 40 days. (The required amount of lido card is reduced by one-fifth, which improves the safety and quality)
- the subject is a college student, female, height 1.60m, weight 80kg
- the distribution ratio of local anesthetic analgesic delay agent is:
- the above ingredients were added in proportion to 2% lidocaine 400 ml solution, 0.9% physiological saline was added to 10000 ml, and then a fan-shaped subcutaneous injection was performed on the surgical site of the patient with a 15-20 cm injection needle. The result was anesthesia.
- the onset time was shortened from 5 minutes for pure lidocaine to 60 seconds, and the duration of analgesia was extended from 2 hours to 40 days.
- the operation lasted for 10 hours, a total of 8100ml of fat was pumped out, and returned to the ward after surgery. After 3 months, the weight was reduced by 15 kg.
- the surgeon will select a single or compound local anesthetic according to the individual's condition, and may also add some additives to ensure the safety and effect of the operation.
- some additives for example, 1% epinephrine hydrochloride, 0.9% saline for injection, etc., in addition, can also be compatible with alkaline local anesthetics, the effect is better.
- these measures are not within the scope of the invention and are not described in detail.
- the surgeon can fully select some of the necessary measures to ensure the safety of the surgery in accordance with the formulation of the present invention and on a case-by-case basis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167001606A KR101800851B1 (ko) | 2013-08-20 | 2014-07-10 | 국소 마취제 작용 시간 연장 진통제 |
US16/464,326 US20190381061A1 (en) | 2013-08-20 | 2014-07-10 | Local anesthesia pain-relieving time-delay agent |
EP14838087.6A EP3045179B1 (en) | 2013-08-20 | 2014-07-10 | Local anesthesia pain-relieving time-delay agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310364295.6A CN103393714B (zh) | 2013-08-20 | 2013-08-20 | 局麻药止痛延时剂 |
CN201310364295.6 | 2013-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015024420A1 true WO2015024420A1 (zh) | 2015-02-26 |
Family
ID=49557569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/081969 WO2015024420A1 (zh) | 2013-08-20 | 2014-07-10 | 局麻药止痛延时剂 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190381061A1 (zh) |
EP (1) | EP3045179B1 (zh) |
KR (1) | KR101800851B1 (zh) |
CN (1) | CN103393714B (zh) |
WO (1) | WO2015024420A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103393714B (zh) * | 2013-08-20 | 2015-08-26 | 李赴朝 | 局麻药止痛延时剂 |
RU2624901C2 (ru) * | 2015-10-05 | 2017-07-07 | Елизавета Геннадьевна Полунина | Средство для аппликационной анестезии с антисептическими, оптикокератопротективными свойствами и способ его применения в офтальмологии |
CN107115354A (zh) * | 2017-07-03 | 2017-09-01 | 山东中牧兽药有限公司 | 一种复合维生素b注射液及制备方法 |
CN109276718A (zh) * | 2018-10-09 | 2019-01-29 | 蓝可彰 | 含亚甲蓝注射液的组合封闭液及其应用 |
WO2021245432A2 (en) * | 2020-06-01 | 2021-12-09 | Biohellenika S.A. | New pharmaceutical compositions for treatment of covid-19 patients, sepsis and hypoxemia |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1075081A (zh) | 1992-02-01 | 1993-08-11 | 解放军陆军第44医院 | 复方胶体麻醉剂的配制方法 |
CN1266685A (zh) * | 2000-01-29 | 2000-09-20 | 吉特生物技术(武汉)有限公司 | 长效复方镇痛药产品制备的技术工艺方法 |
CN1382443A (zh) | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
CN1709504A (zh) * | 2005-07-12 | 2005-12-21 | 李赴朝 | 局麻药增效延时剂 |
CN103393714A (zh) * | 2013-08-20 | 2013-11-20 | 李赴朝 | 局麻药止痛延时剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239456A (zh) * | 2013-04-26 | 2013-08-14 | 临江市妇幼保健院 | 一种镇痛药物组合物及其用途 |
-
2013
- 2013-08-20 CN CN201310364295.6A patent/CN103393714B/zh active Active
-
2014
- 2014-07-10 US US16/464,326 patent/US20190381061A1/en not_active Abandoned
- 2014-07-10 WO PCT/CN2014/081969 patent/WO2015024420A1/zh active Application Filing
- 2014-07-10 KR KR1020167001606A patent/KR101800851B1/ko active IP Right Grant
- 2014-07-10 EP EP14838087.6A patent/EP3045179B1/en not_active Not-in-force
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1075081A (zh) | 1992-02-01 | 1993-08-11 | 解放军陆军第44医院 | 复方胶体麻醉剂的配制方法 |
CN1266685A (zh) * | 2000-01-29 | 2000-09-20 | 吉特生物技术(武汉)有限公司 | 长效复方镇痛药产品制备的技术工艺方法 |
CN1382443A (zh) | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
CN1709504A (zh) * | 2005-07-12 | 2005-12-21 | 李赴朝 | 局麻药增效延时剂 |
US7928141B2 (en) * | 2005-07-12 | 2011-04-19 | Fuchao Li | Synergistic compositions and methods for enhancing potency and/or for prolonging the duration of action of anesthetics |
CN103393714A (zh) * | 2013-08-20 | 2013-11-20 | 李赴朝 | 局麻药止痛延时剂 |
Non-Patent Citations (1)
Title |
---|
"Commercial Drug Notebook, 3d edition,", 2007, INMIN PUBLISHER, article "p 510 p 674, p 713, p 1089, p 1175," |
Also Published As
Publication number | Publication date |
---|---|
EP3045179B1 (en) | 2019-05-01 |
CN103393714B (zh) | 2015-08-26 |
EP3045179A1 (en) | 2016-07-20 |
EP3045179A4 (en) | 2017-01-25 |
CN103393714A (zh) | 2013-11-20 |
US20190381061A1 (en) | 2019-12-19 |
KR20160061960A (ko) | 2016-06-01 |
KR101800851B1 (ko) | 2017-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105142625B (zh) | 用于长效局部麻醉的新蛤蚌毒素组合配制品 | |
WO2015024420A1 (zh) | 局麻药止痛延时剂 | |
Batra et al. | Dose response study of caudal neostigmine for postoperative analgesia in paediatric patients undergoing genitourinary surgery | |
Yücel et al. | Effects of 2 different doses of pregabalin on morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind clinical trial | |
KR101243519B1 (ko) | 국부 마취약의 마취시간 지연제 | |
Wen et al. | Application of nalbuphine in trigeminal ganglion pulse radiofrequency surgery in patients with postherpetic neuralgia | |
CA1169774A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
US20160051582A1 (en) | Pharmaceutical composition for treatment of chronic pain | |
Yu et al. | Transdermal fentanyl for management of cancer pain in elderly patients in China | |
RU2286791C1 (ru) | Способ лечения рубцов | |
Rajendra et al. | Comparative study of 0.5% bupivacaine and 0.5% bupivacaine plus buprenorphine for brachial plexus block | |
Moeen et al. | Impact of a transversus abdominis plane block with low-dose magnesium sulphate coupled to bupivacaine on postoperative pain after laparoscopic cholecystectomy: A randomized trial | |
JP5274071B2 (ja) | 線維筋痛症治療剤 | |
CN107281183B (zh) | 一种镇痛药物组合物 | |
Singh et al. | Comparative study of duration of analgesia with epidural bupivacaine & bupivacaine with tramadol in lower limb and lower abdominal surgeries | |
Tennant Jr | (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids | |
CN109276718A (zh) | 含亚甲蓝注射液的组合封闭液及其应用 | |
RU2286162C1 (ru) | Способ лечения кожных проявлений склеродермии | |
CN103432575B (zh) | 一种治疗神经性皮炎的复合生物制剂 | |
CN111671754A (zh) | 盐酸青藤碱在制备治疗肋骨骨折疼痛药物中的应用 | |
Ong-Lam et al. | Opiate sparing effects of cannabinoid in CRPS patients | |
Štefančić et al. | Liječenje patološke karcinomske boli lokalnom primjenom morfija | |
TW201828941A (zh) | 一種點鼻劑或噴鼻劑組合物 | |
Irving et al. | NGX-4010, a high-concentration capsaicin patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia | |
Ong-Lam | Treatment of refractory post herpetic neuralgia with cesamet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14838087 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20167001606 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014838087 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014838087 Country of ref document: EP |